drugset / Trial / NCT00149799
Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
Phase 3
Completed
100 enrolled
Massachusetts General Hospital
National Institute of Mental Health (NIMH) · collabRhode Island Hospital · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study's primary aim is to compare time to relapse and relapse rates in responders to acute escitalopram who are then randomized to placebo versus continuation treatment with escitalopram.
Timeline
- Start
- 2005-05
- Primary completion
- 2013-03
- Completion
- 2013-03
Outcome
Met primary endpoint
registry Phase II: Escitalopram vs Phase II: Placebo; p = 0.048; Hazard Ratio (HR) 2.73 (95% CI 1.01 to 8.59); Regression, Cox NCT00149799 ↗
Publications
- Fang A, Porth R, Phillips KA, Wilhelm S. Personality as a Predictor of Treatment Response to Escitalopram in Adults With Body Dysmorphic Disorder. J Psychiatr Pract. 2019 Sep;25(5):347-357. doi: 10.1097/PRA.0000000000000415.
- Weingarden H, Shaw AM, Phillips KA, Wilhelm S. Shame and Defectiveness Beliefs in Treatment Seeking Patients With Body Dysmorphic Disorder. J Nerv Ment Dis. 2018 Jun;206(6):417-422. doi: 10.1097/NMD.0000000000000808.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Escitalopram | Small molecule | 30 mg | — |